Whistleblower Protections for FDA and Private-Sector Employees

DSpace/Manakin Repository

Whistleblower Protections for FDA and Private-Sector Employees

Show simple item record

dc.contributor.advisor Hutt, Peter Barton en_US
dc.contributor.author Rouse, John en_US
dc.date.accessioned 2012-07-06T20:31:48Z
dc.date.issued 2005 en_US
dc.identifier.citation Whistleblower Protections for FDA and Private-Sector Employees (2005 Third Year Paper) en
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:8965546
dc.description.abstract The goal of this paper is to provide an introduction to the whistleblower protection laws that impact the FDA as well as publicly traded pharmaceutical companies. The paper begins by discussing the recent developments surrounding Merck’s voluntary recall of Vioxx. The discussion focuses on the fact that Merck allegedly knew of the drugs safety issues yet kept it on the market for several years, even seeking additional indications from the FDA. The paper looks at David Graham’s involvement as a whistleblower and examines his best avenue for redress against retaliation, the Whistleblower Protection Act of 1989. Following the discussion of the Whistleblower Protection Act, the paper considers what the options would have been were a whistleblower to come from within a pharmaceutical company instead of from the FDA. That discussion revolves around the Sarbanes-Oxley Act. I outline how and why Sarbanes-Oxley applies to pharmaceutical companies and then move to an analysis of the Act’s statutory language, outlining how one would bring a Sarbanes-Oxley whistleblower claim procedurally. Following this discussion, the paper gives a cursory analysis of other whistleblower retaliation statutes and issues, attempting to alert the reader that there are other avenues available and that additional considerations may be necessary, depending on the particular circumstances surrounding the retaliatory action. The paper concludes by looking at the current whistleblower climate and suggesting that the FDA may need its own whistleblower statute, particularly if courts begin to reign in Sarbanes-Oxley’s currently widening scope. en
dc.language.iso en_US en
dash.license LAA en_US
dc.subject Food and Drug Law en
dc.subject whistleblower en
dc.title Whistleblower Protections for FDA and Private-Sector Employees en
dc.type Paper (for course/seminar/workshop) en_US
dc.date.available 2012-07-06T20:31:48Z

Files in this item

Files Size Format View
Rouse05.pdf 237.8Kb PDF View/Open
Rouse05.rtf 226.4Kb RTF file View/Open
Rouse05.html 157.7Kb HTML View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters